Key Drivers
- Strong cash flow
- Thin liquidity
- Higher leverage
AIAI Summary
JNJ is increasingly a re-rating story from defensive dividend payer to large-cap growth compounder as new products and medtech momentum offset Stelara erosion, but with litigation and patent risk still hanging over a richer valuation, the better near-term read is to buy only on pullbacks rather than chase the breakout.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Strong cash flow
- •Thin liquidity
- •Higher leverage
Johnson & Johnson remains a high-quality cash generator with strong profitability and dividend support, but thin liquidity, moderate leverage, heavy intangibles, and a richer quarterly valuation temper the case.
Price Behavior
Key Price Behavior Insights:
- •Higher highs
- •Breakout support
- •Extended rally
JNJ's break to a last month high confirms a strong short-term uptrend, but it's extended near the top of its range so a pause or pullback toward $253.97 support is possible.
Quick rebound from a modest pullback to a new high signals strong buying pressure
Sentiment & News
Key News Insights:
- •Defensive Strength
- •Pipeline Investment
- •Patent Headwinds
Johnson & Johnson's recent headlines were mostly constructive, highlighting its defensive healthcare profile, steady growth and dividend appeal, while strategic investments and pipeline expansion offset ongoing patent and biosimilar pressures.
The news flow supports a generally positive near-term view on J&J, with upside tied to growth execution and capital deployment, though product and patent risks remain a drag
Similar Companies in Healthcare
Other companies in the same sector with AI ratings